Public Institutions
2006
1-10 Employees
Fundacja Klaster LifeScience KrakówThe Klaster LifeScience Krakow (KLSK) is a cluster initiative representing an innovation ecosystem involving six groups of interest: businesses, academia, research & innovation, hospitals, business support, and local government. Our strategy and programmes support the growth of the entire ecosystem, not just the partners in the cluster network.
KLSK is the strategic partner of regional authorities in implementing the RIS3 strategy, with “life sciences” serving as the model for regional smart specialisation. We have experience in H2020 projects and received the Seal of Excellence for the “European Digital Innovation Hub – HealthGoDigital” project proposal.
We facilitate the LSOS open collaboration platform to build a life science and health-oriented innovation ecosystem. We are actively involved in two relevant international networks: the Council of European BioRegions and ScanBalt.
We annually organise the international event Life Science Open Space (www.LSOS.info), an open innovation forum dedicated to collaboration for health and quality of life. KLSK has the capacity to collaborate with the central government and effectively facilitate dialogue with regional governments, translating into the ability to deliver results in terms of policy execution.
Finally, our experience in applying systems thinking tools and methods can help to develop and solve complex problems related to innovation ecosystems.
Address
Michała Bobrzyńskiego 14, 30-348 Kraków, Poland
Social Media
Commercial Register
Foundation
6762464304

Details

Business Model
Klaster LifeScience Krakow is a member-driven network involving six areas of interest: (1) biotechnology and life science business (BioF), (2) research & development (R&D), (3) science and education (Edu), (4) healthcare (Med), (5) business support (Biz), and (6) local government (Gov). Would you be interested in joining the cluster network? Please check the details on www.lifescience.pl.

Videos

News

11/19/26

Your VR Pilot Worked. Will a Hospital Buy It?

A successful study can show that a VR health solution is safe and performs as intended – while leaving its strongest selling point untested. At IHT Conference’26, VR Health Champions brought experts and participants together to explore what developers need to prove before a promising technology becomes part of everyday care. Imagine a VR rehabilitation solution designed to reduce therapists’ workloads. The pilot goes well. Safety and performance targets are met. The team has evidence that the technology works. Then a hospital asks: how much staff time does it save? Is it easy to integrate into existing workflows? What impact is it going to have on patient reported outcomes? The study cannot answer. Nobody measured it. This example captured a central problem discussed during the VR Health Champions Thematic Group Meeting at IHT Conference’26 in Lisbon: a pilot can succeed on its own terms and still leave the case for adoption unfinished. Held on 28 October 2026, in Lisbon, the session was titled “From Innovation to Adoption: Market Access and Reimbursement for Digital Health Solutions – Lessons from VR/XR”. Michael Barngrover of XR4Europe moderated the discussion, with expert contributions from András Perényi of Syreon Research Institute and Maria Nascimento of Instituto Pedro Nunes. Through expert insights, practical examples and questions from participants, the meeting explored market access pathways, reimbursement strategies, evidence requirements and the barriers slowing the uptake of digital health solutions. The format mattered. Designed around discussion and peer exchange, the Thematic Group Meeting gave participants space to examine how these challenges affect their own development decisions. A recurring message emerged: developers need to think about the decisions their evidence will support while they can still shape the study. The benefit you promise is the benefit you need to measure For the rehabilitation solution in the example, reducing workload is part of the reason a hospital might introduce it. If the pilot measures safety and performance without examining staff time or workflow, that practical benefit remains an assumption. The same issue applies to other claims. A solution intended to improve patient engagement needs evidence of engagement. A technology promising better treatment outcomes needs measures that can test that promise. These questions affect what a healthcare provider can reasonably conclude from a study. Safety and performance evidence addresses essential requirements. Evidence about time, workflows and patient experience helps explain what introducing the technology would mean for the people delivering and receiving care. That is why the choice of endpoints matters so much. Before asking whether a pilot met its targets, developers should ask whether those targets capture the value they expect the technology to deliver. No clinical investigation does not mean no validation An early exchange addressed a question with direct consequences for development planning: if a formal clinical investigation is not required, how should a manufacturer validate its technology? Maria Nascimento explained that the need for validation evidence remains. “The technical documentation must still contain evidence of validation. Validation needs to show that the technology meets its intended purpose when used by the intended users in the intended environment. This requirement remains relevant whether or not a clinical investigation is mandatory.” The discussion explored how appropriately designed usability studies could also collect endpoints relevant to validation, depending on the technology and applicable requirements. For teams working with limited resources, that creates an important planning opportunity. A study may be able to answer several relevant questions if those questions are defined early enough. The distinction requires care: usability work is not a universal substitute for clinical investigation. The practical lesson is to understand what evidence is needed before deciding how to collect it – i.e. one should start with the evidence gap, not with the study. So the clinical validation is not about doing more studies, but having a clear strategy about generating the right evidence, at the right time, for the right claims. Who needs to be convinced – and of what? A participant’s question about whether a new device must be better than products already on the market opened up a broader issue. “Better” needs a reference point. Better for which patients? Compared with which treatment? Measured through which outcomes? And relevant to whose decision? A manufacturer establishing safety and performance, a payer considering reimbursement and a hospital deciding whether to purchase a technology are assessing different aspects of the same product. In publicly funded healthcare, the discussion also concerns how limited resources should be allocated. Clinical benefit, comparisons with current care, costs and wider value can all become part of that assessment. Even a positive reimbursement decision leaves further work. Clinicians and institutions still need to integrate the solution into practice. User acceptance and practical implementation remain consequential. For developers, this makes adoption a sequence of decisions that each need a convincing answer. Evidence collected for one stage may help with another, but that connection needs to be planned. Digital technology does not automatically mean digital reimbursement András Perényi introduced the VR Health Champions Market Access Landscape Report, developed to help innovators navigate reimbursement routes across European healthcare systems. Its starting point was a practical information gap. “Developers need to know whether reimbursement is possible in a particular country and, if so, which pathway, eligibility conditions and evidence requirements apply. The report aims to make that landscape easier to understand.” Germany, France and Belgium featured in the discussion as examples of countries with more established dedicated approaches. Yet the existence of a digital health pathway does not establish that a particular VR/XR product is eligible. Perényi highlighted three recurring considerations: What delivers the therapeutic effect? Software may be the main therapeutic component, or the intervention may depend on specialised hardware. Where is the technology used? Home use and use within a clinical service can lead to different access considerations. How does it fit into treatment? A standalone intervention may be assessed differently from a tool embedded in a broader care pathway. For immersive health developers, these distinctions can have substantial consequences. A hardware-dependent solution or a tool used within a clinical workflow may need to follow a traditional medical-device reimbursement route. The access strategy therefore has to reflect the actual product and its intended use. Calling a solution “digital” does not resolve the question of how a healthcare system will fund it. The costly question is the one asked after the study Towards the close, the discussion returned to a familiar development pressure: teams concentrate on building the technology and postpone regulatory or market access questions. The consequences may only become visible once a study is complete. A team can have a substantial dataset and still lack an outcome or comparison needed for the next assessment. Collecting that missing evidence may require further work, additional funding and another opportunity to study the intervention. A question about comparators brought the conversation to PICO: population, intervention, comparator and outcomes. Considering these elements early helps connect the study to its eventual purpose, including assessment against the current standard of care. The experts acknowledged that startups cannot do everything at once. Their recommendation was to involve regulatory and market access expertise early where resources allow, while important choices can still be changed. For a resource-constrained team, the value of that advice is concrete: make the evidence budget answer the questions that will matter later. Key takeaways for VR/XR health innovators Design the pilot around the next decision. Identify who will assess, fund, purchase or use the solution, and what they need to know. Turn the value proposition into measurable outcomes. Claims about staff time, workflow, engagement or treatment benefit need evidence that tests them. Plan validation explicitly. When a clinical investigation is not required, determine which validation evidence is still needed to be generated and how it should be performed. Investigate reimbursement eligibility early. Software, hardware, setting of use and the product’s role in treatment can influence the available route. Choose the comparator before collecting the data. The relevant standard of care should inform the study design when future decisions require a comparison. Bring specialist advice in while it can change the plan. Early input can help prevent a completed study from leaving a critical question unanswered. The VR Health Champions meeting connected these challenges through practical examples and participant questions. It showed why evidence planning, reimbursement and implementation need to be considered together, while developers still have room to act. For the next VR pilot, that leaves one useful question: If this study succeeds, what will a hospital know that makes it ready to say yes?

News

11/19/26

The Regulatory Domain within the Healthcare Innovation Cycle

An innovative XR solution may have the potential to transform healthcare, but technological excellence alone is not enough. Understanding regulatory requirements is essential to bringing healthcare innovations safely and responsibly to market. Within VR Health Champions, the Regulatory domain of the Healthcare Innovation Cycle supports four flagship SMEs – MEEVA, MedApp S.A., MetaSkills and dotLumen – in navigating regulatory challenges, strengthening their readiness and making informed development decisions. Every healthcare innovation begins with an ambition to make something better.A new technology may help clinicians perform complex procedures, support rehabilitation, improve accessibility or create more realistic training environments. Yet translating this potential into real-world healthcare applications brings responsibilities that extend beyond technological performance. Innovators must understand which regulatory requirements apply to their solutions, what evidence may be needed and how to demonstrate compliance. For emerging companies, these questions are rarely straightforward. They require specialist knowledge, careful planning and an understanding of how regulatory decisions can influence product development. This is where the Regulatory domain of the Healthcare Innovation Cycle comes into focus. Drawing on the Healthcare Innovation Cycle as a conceptual framework, VR Health Champions connects regulatory expertise with the practical challenges faced by healthcare innovators. “For many healthcare startups, regulatory requirements can seem overwhelming. Our role is to help innovators understand what applies to their solutions, identify the steps they need to take and make informed decisions throughout the development process. Regulatory readiness is not simply about documentation. It is about building safer and more reliable healthcare technologies.” – Cristiana Costa, Instituto Pedro Nunes (IPN) Understanding the rules behind healthcare innovation Developing technology for healthcare means entering one of Europe’s most closely regulated environments. Under the European Union’s Medical Device Regulation (MDR), medical devices are subject to requirements that depend on factors such as their intended purpose and risk classification. These requirements influence the evidence, documentation and conformity assessment procedures needed before a device can be placed on the European market. For companies developing XR technologies, the regulatory picture can be particularly complex. An immersive training platform, an assistive technology or an augmented reality solution supporting medical procedures may serve very different purposes. Their regulatory obligations therefore cannot be assumed to be identical. The intended purpose of a product is fundamental to determining which regulatory requirements apply. Understanding these differences is particularly important for emerging companies, where development teams may have extensive technological expertise but limited experience navigating medical device regulations. Within VR Health Champions, the Regulatory domain addresses this challenge through individual regulatory assistance tailored to the needs of each flagship SME. Rather than offering a single approach for every innovation, the project recognises that each solution has its own characteristics, development priorities and regulatory considerations. From uncertainty to informed decisions For a start-up developing an innovative healthcare solution, regulatory requirements can sometimes feel like a complicated set of rules standing between an idea and its potential users. But understanding those requirements can also help innovators make better decisions about their products. Within VR Health Champions, regulatory support begins with an assessment of the specific needs and regulatory maturity of each flagship SME. This assessment helps identify potential gaps, clarify applicable requirements and establish priorities for further development. Based on the findings, startups receive one-on-one advisory and mentoring support addressing regulatory processes associated with the medical device lifecycle. The assistance may involve understanding relevant MDR requirements, identifying documentation needs, reviewing regulatory considerations or preparing for activities that support future conformity assessment. Importantly, the support is adapted to the individual circumstances of each company. For some innovators, the priority may be understanding how their solution should be classified. For others, it may involve strengthening regulatory documentation or identifying additional evidence needed to support compliance. The objective is not to impose identical requirements on different technologies, but to help each startup navigate its own regulatory challenges. Regulatory readiness is built through collaboration Regulatory compliance does not exist in isolation from technological development or clinical evaluation. A decision made during product development may influence regulatory documentation. Evidence gathered through verification and validation may help demonstrate that a solution meets relevant requirements. Regulatory considerations, in turn, may inform how a product is designed, tested and refined. This relationship reflects an important principle of the Healthcare Innovation Cycle: progress across the Technology, Clinical, Regulatory and Market/Business domains takes place in parallel, with activities contributing to more than one domain. Within VR Health Champions, regulatory advisory services complement the work carried out across other project activities. As flagship SMEs refine their technologies and engage in verification and validation, regulatory experts help them understand how relevant findings and development decisions relate to their compliance obligations. This collaborative approach encourages innovators to consider regulatory requirements throughout product development rather than treating them as a separate concern. It also brings together different perspectives. Technology developers understand how their solutions work. Clinical experts contribute knowledge of healthcare environments and patient needs. Regulatory specialists help interpret applicable requirements and identify the evidence and documentation necessary to demonstrate compliance. Together, these perspectives support more informed and responsible innovation. “Regulatory readiness develops alongside technological and clinical progress. When developers, clinical experts and regulatory specialists exchange knowledge, it becomes easier to identify requirements early, address potential challenges and build the evidence needed to support future conformity assessment.”- András Perényi, Spherical Research Institute (SRI) Four innovations, different regulatory considerations The four flagship SMEs participating in VR Health Champions demonstrate how different healthcare technologies raise different regulatory questions. MedApp develops advanced medical visualisation and navigation technologies designed to support healthcare professionals during complex medical procedures. MEEVA focuses on immersive autism solutions, while dotLumen develops assistive technology to help people with visual impairments navigate their surroundings more independently. MetaSkills, meanwhile, creates immersive XR training environments that allow healthcare professionals to develop practical skills through realistic simulations. Although these innovations share an ambition to improve healthcare, their intended purposes and technical characteristics differ. So do the regulatory questions their developers need to address. For some, the challenge may involve medical device classification and compliance requirements. For others, demonstrating quality, reliability or suitability for a particular healthcare application may involve different forms of assessment. Understanding these distinctions helps innovators identify the requirements relevant to their solutions and make better-informed development decisions. “Developing an innovative healthcare technology involves much more than making the product work. Understanding the regulatory requirements helps us see what evidence and documentation may be needed and how these considerations should influence our development decisions. Having access to specialised expertise makes that process easier to navigate.” – Maciej Stanuch, MedApp S.A. More than a regulatory checklist For many innovators, CE marking represents an important milestone in bringing a medical device to the European market. However, preparing for conformity assessment involves considerably more than completing a checklist. Depending on the product and its regulatory classification, manufacturers may need to demonstrate compliance through technical documentation, risk management, appropriate evaluation activities and other applicable requirements. These obligations can require substantial expertise, resources and careful planning. For smaller companies, navigating this process without specialist assistance can be particularly challenging. VR Health Champions addresses this challenge by supporting flagship SMEs in strengthening their regulatory maturity. The objective is to help innovators become better prepared for the regulatory processes relevant to their technologies, rather than suggesting that certification can be achieved through a single activity or consultation. Regulatory compliance is not the only area in which healthcare innovators must demonstrate that their solutions meet defined standards. Depending on the nature of the innovation, external evaluation and quality assurance may also play an important role in building credibility and trust. One example comes from MetaSkills, a VR Health Champions flagship SME that recently achieved an important milestone through a process supported by project partner InnoStars (INN). In October 2026, MetaSkills received the EIT Label for Non-Degree Education and Training for its Digital Health Conversations for Healthcare Teams & Professionals: An AI Simulation-Based Training Course. The accreditation followed a process that began in autumn 2025 and was coordinated in collaboration with Instituto Pedro Nunes (IPN), a partner in VR Health Champions. During this period, MetaSkills developed the training programme, defined its learning objectives, prepared AI-powered conversation scenarios and established methods for assessing participants’ competencies. The programme and its supporting documentation were subsequently evaluated by external EIT Health experts, who assessed the coherence of its educational approach, teaching and assessment methods, and quality assurance procedures. The EIT Label confirms that the programme meets specified educational quality standards. Although distinct from medical device certification, the EIT Label demonstrates how independent evaluation can recognise the educational quality of an innovative healthcare training programme. “We want to give healthcare professionals a safe space to practise conversations with patients and colleagues. AI allows them to explore different approaches, receive specific feedback and try again. The EIT Label is an important recognition of the educational quality of our programme, and achieving it demonstrates the value of collaborating with our VR Health Champions partners.” – Kuba Pędziwiatr, Metaskills Innovation carries responsibility Behind every healthcare technology are people who may one day rely on it – patients, healthcare professionals and those responsible for delivering care. For innovators, understanding regulatory requirements is therefore about more than preparing documentation or navigating complex procedures. It is about making informed decisions that help build confidence in the technologies they develop. Through individual assessments, specialist advice and collaboration across the Healthcare Innovation Cycle, VR Health Champions helps its flagship SMEs address these responsibilities as their solutions evolve. Because in healthcare, innovation is not measured by what technology can do alone, but also by the confidence we can place in it.

News

11/19/26

VR Health Champions meets in Lisbon to review progress and plan the next phase

VR Health Champions partners gathered in Lisbon on 28 October 2026 for the project’s General Assembly, reviewing progress and priorities for the next six months. Held during the Innovating Health Together Conference, the meeting coincided with a wider project presence through a dedicated exhibition booth and a thematic session on market access and reimbursement for digital health solutions. The General Assembly at ISCTE – University Institute of Lisbon brought together a review of project activities and planning for the months ahead. The programme focused on progress towards project objectives, connections between work packages, and risks and mitigation measures. The coordination and management session covered deliverables, milestones and performance indicators, alongside the work plan and priorities for the coming six months. Presentations from four companies supported by VR Health Champions – MEEVA, MetaSkills, .lumen and MedApp – formed a central part of the programme. These focused on progress, implementation challenges and planned activities, including support through the Financial Support to Third Parties (FSTP) mechanism. The meeting also addressed the interconnected areas supporting the development of healthcare innovations: technical development and user experience, content and skills, testing and validation, and regulatory and market entry support. Communication, dissemination, exploitation and value chain integration were also on the agenda. Across these areas, the focus was on aligning activities and planning the next six months of work. The project’s presence in Lisbon extended beyond the General Assembly. During IHT Conference on 27–28 October, the VR Health Champions booth gave participants the opportunity to explore solutions from .lumen, MEEVA, MetaSkills and MedApp and meet the teams behind them. VR Health Champions also contributed to the conference programme through the Thematic Group Meeting, “From Innovation to Adoption: Market Access and Reimbursement for Digital Health Solutions – Lessons from VR/XR”. The session addressed market access, reimbursement pathways, evidence requirements and barriers to the adoption of digital health solutions. Michael Barngrover from XR4Europe moderated the discussion, with contributions from András Perényi of Syreon Research Institute and Maria Nascimento of Instituto Pedro Nunes. Bringing the General Assembly together with participation in IHT connected consortium planning with broader conversations about healthcare innovation. It provided an opportunity to review the project’s next steps while showcasing the supported companies and exploring the conditions needed to bring their solutions into healthcare practice.

News

Life Science Landscape

Supporting processes

Support processes in life science innovation facilitate core activities in product development and commercialization.